CAM
CLDX icon

Close Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Close Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-133
Closed -$3K – 272
2025
Q2 		$3K Hold
133
– – ﹤0.01% 234
2025
Q1 		$2K Hold
133
– – ﹤0.01% 238
2024
Q4 		$3K Hold
133
– – ﹤0.01% 232
2024
Q3 		$5K Hold
133
– – ﹤0.01% 236
2024
Q2 		$5K Hold
133
– – ﹤0.01% 236
2024
Q1 		$6K Hold
133
– – ﹤0.01% 233
2023
Q4 		$5K Hold
133
– – ﹤0.01% 221
2023
Q3 		$4K Buy
+133
New +$4.17K ﹤0.01% 219

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Close Asset Management's CLDX Position: Q3 2025 in Review

Close Asset Management sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 133 shares — an estimated $3K sold.

Close Asset Management first reported a position in CLDX in Q3 2023 and held it in 8 quarters. The position peaked at $6K in Q1 2024. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Close Asset Management reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Close Asset Management sold 133 Celldex Therapeutics shares in Q3 2025, an estimated $3K.
  • Close Asset Management first reported a position in Celldex Therapeutics in Q3 2023 and held it in 8 quarters.
  • Close Asset Management's Celldex Therapeutics position peaked at $6K in Q1 2024.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Close Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.